3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Classical hematology
2
Conditions
Anemia
4
Neoplasms
2
Uterine Cervical Neoplasms
1
Thalassemia
1
Myelodysplastic Syndromes
1
Leukemia
1
Hematologic Neoplasms
1
Bone Marrow Failure Disorders
1
Anemia, Sickle Cell
1
Anemia, Aplastic
1
Interventions
Epoetin Alfa
25
Darbepoetin alfa
17
apixaban
9
Rivaroxaban
9
Dalteparin
7
Heparin, Low-Molecular-Weight
6
Surveys and Questionnaires
5
Meropenem
5
fludarabine phosphate
4
Vancomycin
4
Tinzaparin
4
Enoxaparin
4
Cyclosporine
4
Cefepime
4
ferric carboxymaltose
3
edoxaban
3
Whole-Body Irradiation
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Ceftazidime
3
Carboplatin
3
Busulfan
3
Antilymphocyte Serum
3
Amikacin
3
romiplostim
2
peginesatide
2
hematide
2
fludarabine
2
epoetin beta
2
bemiparin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Blood Transfusion
×
Classical hematology
×
Clear all
NCT05255445
2024-05-17
RBC-IMPACT
Westat
Completed
157 enrolled
NCT01116479
2014-11-05
HaemOPtimal
Rigshospitalet, Denmark
Phase 2
Terminated
180 enrolled